Pioneering generative biology to create breakthrough therapeutics.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Investors 2
| Date | Name | Website |
| 26.03.2022 | ARCH Ventu... | archventur... |
| - | Altitude L... | altitudels... |
Mentions in press and media 18
| Date | Title | Description |
| 03.10.2024 | A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore | Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science... |
| 28.08.2024 | Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer | Collaboration leverages Quotient's platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases Quotient and Pioneering Medicines, Flagship's in-house drug development unit, will jointly c... |
| 06.08.2024 | Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner | Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that global... |
| 11.06.2024 | SITC Announces Keynote Speaker Dr. Ignacio Melero at the Immuno-oncology Drug Development Summit | SITC IO Drug Development Keynote Speaker The Society for Immunotherapy of Cancer (SITC) is excited to announce that Ignacio Melero, MD, PhD from the Clinica Universidad de Navarra Medical School and Cima will present his keynote on Cancer I... |
| 16.09.2023 | USA-based Generate:Biomedicines closes Series C financing at USD 270 million | Somerville, USA-based clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, Generate: Biomedicines, closes Series C financing at USD 270 million. The company announced the fundraise on Sep... |
| 15.09.2023 | Generate:Biomedicines Closes $273M Series C Financing | Generate:Biomedics, a Somerville, MA-based clinical-stage biotherapeutics company, raised $273M in Series C funding. Backers included Amgen, NVentures, MAPS Capital (Mirae Asset Group), and Pictet Alternative Advisors. Additionally, company... |
| 28.04.2023 | Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI | Generate:Biomedicines and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cel... |
| 05.12.2022 | Вдохновлено DALL-E: как биолаборатории используют ИИ для изобретения новых лекарств | Недавно сразу две лаборатории независимо друг от друга представили программы на базе диффузионных моделей, которые позволяют создавать новые белки, значительно повышая точность результата. Программа Chroma, разработанная бостонским стартапо... |
| 11.08.2022 | Prellis Biologics hires new CEO, raises $35M towards 3D bioprinted lymph node R&D | Prellis Biologics has raised $35 million and appointed a new CEO as it seeks to advance the development of its proprietary 3D bioprinted lymph node. Raised via a Series C funding round led by Celesta Capital and Avidity Partners, and backed... |
| 01.12.2021 | Digital health news, funding roundup in the prior week; November 29, 2021 | Amazon Health sells healthcare services to Hilton; Athenahealth acquired for $17 Billion Where tech meets weight and mental health. Mental health struggles and unintentional weight fluctuations are strongly linked. Experts state that stress... |
Show more